3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Classical hematology
2
Breast
2
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Conditions
Sarcoma
70
Osteosarcoma
31
Melanoma
22
Sarcoma, Ewing
20
Rhabdomyosarcoma
17
Neuroblastoma
17
Neoplasms
15
Gastrointestinal Stromal Tumors
15
Colorectal Neoplasms
15
Breast Neoplasms
14
Wilms Tumor
13
Liposarcoma
13
Glioblastoma
13
Rhabdoid Tumor
12
Ovarian Neoplasms
12
Neoplasm Metastasis
12
Bone Neoplasms
12
Hepatoblastoma
11
Gliosarcoma
11
Desmoid Tumors
11
Carcinoma, Non-Small-Cell Lung
11
Thyroid Neoplasms
9
Stomach Neoplasms
9
Neurofibrosarcoma
9
Medulloblastoma
9
Glioma
9
Recurrence
8
Neuroectodermal Tumors, Primitive, Peripheral
8
Lymphoma, Non-Hodgkin
8
Lymphoma
8
Interventions
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Irinotecan
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Sarcoma
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled